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Illicit  drug  use  is  a  largely  hidden  phenomenon  and  population  measures  are  notoriously 
problematic. Reliable  and  valid data  for  local, regional  and  national  public  health and other 
interventions are needed.  To address this information we examined temporal trends within and 
across weeks in methamphetamine (MA) in a single location in order to inform a sampling plan 
for understanding long-term trends in MA use based on sampling raw influent to waste water 
treatment plants.  The measured concentrations in wastewater are used to estimate the total mass 
of  MA  consumed  MA  rather  than  the  number  of  doses  due  to  the  uncertainty  surrounding 
methamphetamine purity, mass of MA per dose, and the number of doses used per day.  Results 
from a region with high levels of MA use indicate that MA levels do not differ significantly 
between weekdays and weekends (p=0.1), consistent with a predominately regular, daily use 
pattern  use.    The  potential  contribution  of  legal  sales  of  d-  and  l-MA  to  the  mass  of  MA 
consumed  within  the  community  was  estimated  to  range  from  3-8%.    Limitations  and 
uncertainties  associated  with  estimating  the  mass  of  MA  consumption  include  small 
contributions of prescription and over-the-counter drugs that are metabolized to MA as well as 
measurement and sampling variability.  
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INTRODUCTION  1 
The use of illicit drugs is a largely hidden phenomenon and determining valid,  2 
accurate population estimates of usage are extremely challenging (National Institute of  3 
Drug Abuse 2006). Reliable and valid data for local, regional and national planning are  4 
needed. Methamphetamine is an example of a drug which is increasingly abused  5 
worldwide (United Nations Office on Drugs and Crime 2009), but for which specific,  6 
local geographic and temporal patterns of use are poorly documented.  7 
Use of illicitly manufactured methamphetamine has had a substantial impact on  8 
public health throughout much of East and South-East Asia (United Nations Office on  9 
Drugs and Crime 2009), Australia (Cate et al. 2009), and some regions of North America  10 
(Maxwell  and  Rutkowski  2008).   While  methamphetamine  abuse  dominates  much  of  11 
Asia, amphetamine abuse is more common in Europe and the Near and Middle East and  12 
is  also  available  by  prescription  in  the  US.    Methamphetamine  is  present  in  Europe,  13 
though generally at lower levels than amphetamine and cocaine (European Monitoring  14 
Centre  for  Drugs  and  Drug  Addiction  2009).  Trends  in  methamphetamine  use,  15 
manufacturing,  and  distribution  are  very  fluid,  with  frequent  changes  and  much  16 
geographic  variability  in  use,  manufacturing  and  sources  (Cunningham  et  al.  2010;  17 
United  Nations  Office  on  Drugs  and  Crime  2009).  The  geographic  variability  for  18 
methamphetamine is more pronounced than for most other drugs of abuse in the United  19 
States, Mexico and Canada (Caulkins 2003; Maxwell and Rutkowski 2008).     20 
Patterns of MA consumption appear to vary dramatically across and within US  21 
communities.  In the Western United States and parts of the Midwest there appear to be  22 
substantial populations of regular MA users as well as those who use only intermittently  23 Interpreting Methamphetamine Levels 
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while in areas of the Eastern and Midwestern United States, for instance New York City  24 
and Chicago, the total proportion of the population that uses MA appears to be much  25 
lower and most use appears to be intermittent (National Institute on Drug Abuse 2010).  26 
The State of Oregon, in the Western region of the United States, is an area with relatively  27 
high rates of MA use in which many users are believed to be regular users MA (National  28 
Drug Intelligence Center 2009; Sudakin and Power 2009).  29 
Unlike many other illicit drugs such as cocaine and heroin, MA use is often as  30 
common,  if  not more common,  in  less  metropolitan areas  (Office of  Applied Studies  31 
2007). These less populated locales are areas for which accurate drug usage data can be  32 
difficult to obtain.  Testing of raw influent wastewater from wastewater treatment plants  33 
(WWTPs) can provide a relatively  low cost, widely applicable  methodology  for drug  34 
surveillance  (Frost  et  al.  2008).  Data  based  upon  samples  collected  from  municipal  35 
WWTPs in the State of Oregon in 2008 indicated the presence of MA in every one of 96  36 
municipalities tested, of which 35% were small rural towns, 27% large rural city/towns,  37 
and  38%  urban  (Banta-Green  et  al.  2009).  This  contrasted  with  cocaine,  which  was  38 
identified in 90% of municipalities, and 3,4-methylene-dioxy methamphetamine (MDMA  39 
or  ecstasy)  in  63%.    Methamphetamine  is  detected  in  raw  wastewater  from  other  40 
countries  as  well;  however,  those  in  Europe  have  generally  reported  much  lower  41 
concentrations and loads (mass/person/day) than found in the United States as well as  42 
detection in a smaller proportion of municipalities (Boles and Wells 2010; Postigo et al.  43 
2008a; van Nuijs et al. 2009a).     44 
Patterns of MA use are poorly described. Estimates indicate that the average days  45 
of use in a month may be higher for MA than for cocaine (Cate et al. 2009; Simon et al.  46 Interpreting Methamphetamine Levels 
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2002).  Wastewater sampling for systematic drug abuse epidemiology and surveillance  47 
purposes is unlikely to be obtained on a daily basis due to cost and logistical reasons.   48 
Therefore, there is a need to discern the temporal pattern of MA loads so that a valid,  49 
efficient,  and  cost-effective  plan  for  sampling  WWTPs  can  be  developed  for  use  in  50 
monitoring the long-term temporal trends in MA consumption at the community scale.  51 
Few estimates of the amount of MA consumed based on measured levels in influent raw  52 
wastewater samples are reported (Chiaia et al. 2008; Huerta-Fontela et al. 2008b; Zuccato  53 
et al. 2008)  Accurate estimates of MA  loads are needed  in order to make summary  54 
judgments  about  both  the  absolute  and  the  comparable  level  of  excretion  (and  55 
consumption) over time and between places.  56 
While it is expected that most MA detectable in wastewater in Oregon is from  57 
illicit sources, MA also has legal sales of the d- (as Desoxyn) and l-forms (e.g., Vicks  58 
inhaler) as well as drugs that are metabolized to form d- and l-MA (e.g., Selegiline,  59 
Famprofazone, and Benzphetamine). Ascribing MA (or any other illicit drugs with a  60 
range of possible origins) to illicit use at the whole municipality level faces the same  61 
challenges as those attempting to determine the source of MA detected in an individual.   62 
To the best of our knowledge, potential contributions of legal uses of MA or drugs that  63 
are metabolized to MA have not been examined critically.  For such analyses, data from  64 
communities where MA is readily detected due to high use levels is ideal.    65 
The aims of this study are to 1] describe the temporal patterns of MA use across  66 
days  of  the  week  for  a  single  location  with  endemic  MA  use  in  order  to  inform  a  67 
sampling plan for discerning long-term trends in MA use, 2] estimate the mass of MA  68 
consumed  within  the  community  as  back-calculated  from  measured  loads  in  the  69 Interpreting Methamphetamine Levels 
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community’s influent wastewater, and 3] estimate the contribution of legal sources of  70 
MA to wastewater loads.   71 
    72 
1  MATERIALS AND METHODS  73 
  2.1 Sample Collection.  A total of fifty-four 24hr flow-normalized composites of  74 
raw wastewater influent were collected during three periods.  Period 1 was 17 days in  75 
July and August 2007; Period 2 was 18 days in September and October 2007; and Period  76 
3 was 22 days in March and April 2008. The WWTP sampled is located in the Pacific  77 
Northwest and serves a population of 55,000 and treats around 90% domestic and 10%  78 
industrial waste.  The location was selected because the sewer system and daily  79 
composite sampling approach are well characterized and the staff has consistently been  80 
cooperative with the investigators for several years. It is for these reasons that the  81 
location was included in earlier studies (Banta-Green et al. 2009; Chiaia et al. 2008).   82 
Flow-normalized composites were collected on ~ 20 min intervals over 24 hr periods and  83 
the composites were housed in a 4 
oC compartment during collection.  Composite  84 
samples were transferred into individual 150 mL high density polyethylene bottles (VWR  85 
International, West Chester, PA) and transported back to the laboratory at Oregon State  86 
University where they were frozen immediately and stored at -20 
◦C until analysis.  The  87 
samples were analyzed within two weeks of collection. Preliminary test indicated no loss  88 
of MA upon centrifugation, storage in polyethylene bottles, and storage over the two  89 
week period.  90 
  2.2 Large-Volume, Direct Injection Liquid Chromatography/Tandem Mass  91 
Spectrometry.  The standards, reagents and analytical method has been previously  92 Interpreting Methamphetamine Levels 
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described (Chiaia et al. 2008). Briefly, 7 mL of raw influent was centrifuged for 30 min.   93 
After centrifugation, supernatant was transferred to a 6 mL autosampler vial and spiked  94 
with (±) methamphetamine-d5 as the internal standard. Large-volume (1,800 L), direct  95 
injection and separation was performed on a modified Agilent 1100 system (Santa Clara,  96 
CA) (Chiaia et al. 2008) that was fitted with a C18 security guard column (Phenomenex,  97 
Torrance, CA) and a 150 × 4.6 mm × 5 μm particle size Atlantis T3 C18 column (Waters  98 
Corp., Milford, MA).  Detection and quantification of analytes was performed on a  99 
Waters Quattro Micro tandem mass spectrometer (Milford, MA) operated in positive  100 
mode with an electrospray ionization interface (ESI).  The accuracy of the method was  101 
demonstrated with statistically equivalent (95% CI) concentrations determined by  102 
standard addition and solvent-based calibration curves.  The lower limit of quantification  103 
for MA was 10 ng/L. The method precision for MA was 4% for within-day and 8%  104 
between days.     105 
  2.3 Statistical Analysis.  Data were analyzed with the ‘mixed procedure’ in SAS  106 
(version  9.2)  using  a  first-order  autoregressive  model  for  the  correlation  between  107 
observations and fixed effects period, weekend (binary variable: Sat-Sun/Mon-Fri), and  108 
period by weekend interaction (to allow day of the week effects to vary between periods).   109 
2.4 Index Loads (mg/person/day). Index loads were calculated by multiplying  110 
the measured concentration (ng/L) by the measured average flow (L) provided by WWTP  111 
personnel (based upon daily flow meter readings) and divided by the estimated total  112 
population served by the WWTP in the sampling periods (54,890 in 2007 and 54,880 in  113 
2008) (Proehl 2009). The index loads of MA are reported as mass (mg) per population  114 
per day (mg/person/day).  To estimate the uncertainty in the computed loads (error bars  115 Interpreting Methamphetamine Levels 
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shown in Figure 1), the error about the concentration (measured concentration x the  116 
between-day precision of 15%) was then multiplied by the flow for each day and divided  117 
by population.     118 
  119 
2  RESULTS AND DISCUSSION  120 
2.1 Statistical Analysis and Temporal Trends in Loads.  Methamphetamine (MA)  121 
was quantified in each sample collected with concentrations ranging from 120 to 780  122 
ng/L.  Total index loads ranging from 0.13 ± 0.02 to 0.38 ± 0.06 mg/person/day (Figure  123 
1). Methamphetamine levels do not differ significantly between weekdays and weekends  124 
(p=0.1),  consistent  with  a  predominately  regular,  daily  use  pattern  use  within  the  125 
community.  126 
The observed concentrations of MA for raw influent are similar to those observed  127 
in a previous studies with samples from the western US (Banta-Green et al. 2009; Chiaia  128 
et al. 2008) but much greater than those reported by others for locations in the US (e.g.  129 
Kentucky with concentrations ranging from not detected to 100 ng/L) (Loganathan et al.  130 
2009).  Methamphetamine concentrations in other countries are < 20 ng/L (Bijlsma et al.  131 
2009; Castiglioni et al. 2006; Postigo et al. 2008b; van Nuijs et al. 2009b) except for two  132 
reports for Spain in which values ranged from 2-277 ng/L (Huerta-Fontela et al. 2008b)  133 
and in Switzerland where MA in wastewater ranged from below the LOQ up to 27 ng/L  134 
(Berset et al. 2010).  135 
Because concentrations are influenced by the flow of wastewater (dilution) and  136 
the  population  utilizing  the  WWTP  systems,  loads  are  computed  to  facilitate  137 
comparability within location, as in this study, and between locations.  The computed  138 Interpreting Methamphetamine Levels 
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index loads for MA are consistent with those published in an Oregon-wide study (Banta- 139 
Green et al. 2009) and appear to be greater than the MA loads reported by others (Huerta- 140 
Fontela et al. 2008b; Zuccato et al. 2008).   141 
The statistical analysis (n=54) does not give evidence of interaction between each  142 
of the three sampling periods and weekend dates for MA (p=0.2), that is the lack of a  143 
change in loads on weekends did not differ by sampling period (Figure 1).  In this study  144 
we found that MA levels do not differ significantly between weekdays and weekends.   145 
The implication for sampling of this finding is that in an endemic area sampling could  146 
reasonably be done on any day(s) of the week.   147 
There was a significant period effect for MA (p=0.001) in period 3 which was  148 
significantly different than period 1 (p=0.0003) and period 2 (p=0.0018) and there was no  149 
significant difference between periods 1 and 2 (p=0.2). Limited data on temporal trends  150 
in MA from Spain, a country with low MA use levels, indicated concentrations above  151 
detection on weekends but below detection on weekdays (Huerta-Fontela et al. 2008b).   152 
2.2 Estimating Mass of Methamphetamine Consumed.  Back calculating the  153 
number of illicit drug doses and users is an exercise that has been performed primarily for  154 
other substances of abuse including cocaine (Banta-Green et al. 2009; Huerta-Fontela et  155 
al. 2008a; Zuccato et al. 2008) and heroin (Zuccato et al. 2008).  Although percentages of  156 
MA excreted for back calculations are presented (Boles and Wells ; Zuccato et al. 2008),  157 
to the best of our knowledge, few calculations have been performed using measured MA  158 
levels in wastewater due to the low and intermittent detection of MA (Postigo et al.  159 
2010).  160 Interpreting Methamphetamine Levels 
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Although amphetamine is major a metabolite of MA and occurs at quantifiable  161 
levels in wastewater (Banta-Green et al. 2009; Chiaia et al. 2008), amphetamine is sold  162 
legally in the US and thus its occurrence cannot be attributed solely to MA use.  In  163 
addition, while standards are available for hydroxy-methamphetamine, no stable-isotope  164 
labeled standards are available for hydroxy-methamphetamine.   165 
Pharmacokinetic studies on d- and l-MA reveal that 37 to 54% is excreted within  166 
24 hrs as MA (Cook et al. 1993; Cook et al. 1992; Cruickshank and Dyer 2009; Kim et  167 
al. 2004; Li et al. 2010; Oyler et al. 2002).   Detailed studies on the pharmacokinetics of  168 
MA indicate that the percentage of MA excreted by users may be treated as independent  169 
of dose and the route of administration.  For example, the percent of MA excreted as MA  170 
in urine when MA is smoked (36.8±11.1%) (average ±95%CI) and via intravenous  171 
injection (45.0±24.4%) are not statistically different (Cook et al. 1993). Cook et al. (Cook  172 
et al. 1992) found no difference in the pharmacokinetics of a low and high doses of MA  173 
administered over a 15 day period (Logan 2002).  Therefore, the pharmacokinetics (e.g.,  174 
the percent mass of MA per dose excreted over time) can be assumed to be similar for all  175 
routes of uptake and for users of high and low doses.    176 
However, we argue that estimating the number of illicit MA doses is problematic.   177 
First, purity (percent as the d- form) in the Seattle-King county area (located in  178 
Washington state, north of Oregon), which has similar patterns of MA use as well as  179 
sources, varied widely during the study period (0-99%) (National Institute on Drug  180 
Abuse 2008) while the national estimate of average purity for 2007 in the US was 41%  181 
during autumn of 2007.  Furthermore, MA potency has changed over time and MA users  182 
compensate for decreasing potency and/or purity with increasing consumption (Lee et al.  183 Interpreting Methamphetamine Levels 
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2007).  For example, potency declined with increasing regulation limiting sales of  184 
ephedrine and pseudoephedrine precursors in the US, Canada, and Mexico (Cunningham  185 
et al. 2009) and the switch to precursors that lead to racemic mixtures with decreased  186 
potency. While potency may change, the pharmacokinetics of the d- and l-MA forms are  187 
similar (Li et al. 2010; Mendelson et al. 2006); thus, the mass of MA excreted is not  188 
influenced by potency.  For these reasons, we have elected to present the total mass of  189 
MA consumed based on measurements of MA concentrations, total flow of wastewater,  190 
and a range of excretion rates obtained from the literature rather than a single value,  191 
which is likely more representative of the variation that occurs among MA users.    192 
For this study, the lower and upper bound of MA consumed were estimated  193 
assuming 50% and 30% excretion of MA ingested on a g/g basis, respectively. For  194 
sampling Period 1, the lower estimated mass of MA consumed ranged from 18±1 to 31±2  195 
g while the upper estimates of MA mass consumed ranged from 31±2 to 52±4 g (Table  196 
1).   While the estimated lower and upper masses of MA consumed in sampling Period 1  197 
and 2 were not statistically different at the 95% CI (Table 1), they were statistically  198 
higher than those of Period 3 (Table 1).    199 
  3.3 Legal Sales of d-and l-Methamphetamine.  Desoxyn is a prescription drug  200 
that contains d-MA and its sales are tabulated by three digit zip code for each of the 50  201 
states in the US.  The total sales of d-MA for the 973 zip code for Oregon in the third  202 
quarter of 2007 (July – September) was 11.6 g (Drug Enforcement Administration).  In  203 
2007, the population of the studied municipality studied was 11.1% of the total  204 
population for the three digit zip code (Proehl 2009).  Assuming that the mass of d-MA is  205 
evenly consumed over the 90 day period, we estimate that a per capita consumption of  206 Interpreting Methamphetamine Levels 
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2.2 x 10
-7 g/day/person.  Given the range in excretion rates (30 to 50%) of MA, the mass  207 
of MA consumed that potentially can be attributed to the prescription use of Desoxyn  208 
ranges from 3-5 % in Periods 1 and 2 to 5-8% in Period 3 (Table 1).    209 
Our laboratory, and those of others who measure MA in wastewater, do not  210 
distinguish between the d- and l-forms of MA, thus total MA (d- plus l-forms)  211 
concentrations are reported for wastewater.  There is a single report demonstrating the  212 
potential to separate the enantiomers of MA in wastewater (Kasprzyk-Hordern et al.);  213 
however, MA levels in the samples obtained from location in the United Kingdom were  214 
below quantification levels.  Until chiral separations of MA enantiomers are performed,  215 
other potential sources of d- and l-MA must be considered as well as other drugs that are  216 
metabolized to the two forms of MA since they are not analytically distinguished during  217 
the analysis of wastewater.  Just as in forensic science, where other sources potentially  218 
confound the attribution of MA detection to illicit MA consumption (Cody 1996; Logan  219 
2002; Nishida et al. 2006) the same issues are important when considering consumption  220 
at the whole municipality scale.  221 
3.4 Other Pharmaceuticals that Metabolize to form Methamphetamine.  A  222 
source of l-MA is from the use of Vicks inhaler (Logan 2002).  While it is difficult to  223 
estimate the amount of Vick’s inhaler used within the northwest municipality studied, the  224 
over-the-counter product is sold throughout the nation.  Assuming similar usage and  225 
prevalence of the over-the-counter medication, if usage of the inhaler resulted in MA in  226 
wastewater, then quantifiable levels of MA should be nationwide.  However, MA  227 
concentrations were below the limits of detection in wastewater collected from locations  228 
in the northeastern US (unpublished data).  The absence of detectable MA in northeastern  229 Interpreting Methamphetamine Levels 
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U.S. wastewater as well as many European cities indicates that the potential contributions  230 
of the l-MA in Vick’s inhalers is low.  The absence of MA in wastewater from locations  231 
in the northeastern US is consistent with the low prevalence of illicit MA use (National  232 
Institute on Drug Abuse 2008).  233 
Other drugs that humans metabolize to form MA (d- and/or l forms) include  234 
Selegiline, Famprofazone, and Benzphetamine (Logan 2002).  Selegiline is a prescription  235 
drug used for Parkinson’s disease and is metabolized to MA (Nishida et al. 2006;  236 
Romberg et al. 1995).  The prevalence of Parkinson’s disease in the United States is  237 
approximately 1 in every 120-180 people (McInerney-Leo et al. 2004).  Assuming this  238 
level of prevalence, a municipality with ~55,000 residents would result in 300-450 cases  239 
of Parkinson’s disease.  For Parkinson’s disease, Selegiline doses range from 6 mg/day  240 
(transdermal) to 10 mg/day (oral) (2009) and 20% of the parent dose results in MA  241 
excretion (Hasegawa et al. 1999).  Using the published range in doses and urinary  242 
excretion factor along with a conservative estimate that all Parkinson’s disease patients  243 
take Selegeline, which results in an upper estimate of the mass consumed, Selegiline  244 
prescriptions potentially account for 3-6% of the observed MA mass in this study.     245 
Famprofazone is an analgesic that is metabolized to d- and l-MA (5 to 14% of  246 
dose excreted as MA) (Cody 1996; Neugebauer et al. 1997; Tseng et al. 2007); however,  247 
it is not approved for use in the US and is considered an insignificant contributor to the  248 
MA in the study (Hope Personal communication July 23, 2010). Benzphetamine in the  249 
form of Didrex is prescribed for obesity (Cloyd 1997; Cody and Valtier 1998; Stafford  250 
and Radley 2003)  Utilization of Benzphetamine in Oregon is considered low because its  251 
use is greater among those with health insurance and Oregon Medicaid (health insurance)  252 Interpreting Methamphetamine Levels 
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has not approved amphetamines for weight loss (Hope Personal communication July 23,  253 
2010).  However, changes in the prescribing practices for Selegiline and Famprofazone or  254 
the approval and introduction of Famprofazone would potentially impact the MA  255 
residues detected in wastewater.    256 
  257 
3  CONCLUSIONS  258 
Endemic use of MA within a community results in no statistical differences in loads  259 
(mg/person/day) between days.  As a result, it appears reasonable that sampling to  260 
determine MA use in an endemic use area can be accomplished by sampling wastewater  261 
on any day or days of the week.  It also appears that different intra-week patterns of use  262 
may correspond to the stage of community wide drug use, such that areas with few,  263 
occasional users are likely to see peak use on weekends, whereas areas with many,  264 
regular users will have generally constant loads of MA across days of the week.  265 
Therefore, wastewater testing may be of value in determining the stage of drug use for a  266 
community as well as the level of use. This is a premise that warrants further, specific  267 
investigation.   The estimated mass of MA consumed can be determined from wastewater  268 
measurements of concentration and flow.  Calculations to estimate the numbers of MA  269 
doses or users is not, yet, recommended due to the variable purity and unknown patterns  270 
of actual use.  Although there are legal sales of pharmaceuticals containing the d- and l- 271 
forms of MA as well as pharmaceuticals that metabolize to form MA, these sources are  272 
considered relatively minor compared to the illicit use of MA.   273 
  274 
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  450 Table 1.  Lower and upper estimated ranges (average ± 95% CI) of methamphetamine mass for a 
municipality of approximately 55,000 residents for the three sampling time periods in 2007-8.  
  Period 1 
July 13-Aug 5, 
2007 
Period 2 
Sept. 21-Oct. 11, 
2007 
Period 3 
March 25 – April 
15, 2008 
Range in mass of 
methamphetamine 
consumed (g) ± 95% CI 
 
31±2 to 52±4 
 
28±3 to 46±5 
 
18±1 to 31±2 
% attributable to legal 
sales of Desoxyn (l-
form)  
 
3-5 
 
3-5 
 
5-8 
 
 
 
 
 